🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

RecruitingPhase 3Ages 18 Years - anyAllGlaukos Corporation
NCT07495852 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
💊

What it tests

  • Gen 2 Travoprost Intracameral Implant
  • Timolol eye drops 0.5%
  • Sham Procedure
  • placebo eye drops
📍

Where

1 site
Glaukos Investigative Site
Dothan, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy